Race appoints Professor Michael Kelso as Principal Scientist
Race appoints Professor Michael Kelso as Principal Scientist
20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Michael Kelso as Principal Scientist. Prof Kelso will be responsible for providing scientific leadership, developing, managing, and implementing...
MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Zantrene® Drug Combinations
MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Zantrene® Drug Combinations
Race Oncology Limited (“Race”) is pleased to announce a team of researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number...
Race Placement closes oversubscribed & Bonus Option Issue launched for shareholders
Race Placement closes oversubscribed & Bonus Option Issue launched for shareholders
Race Oncology Limited (ASX: RAC) is pleased to announce that it has received binding commitments to raise $5.4m (before associated costs) in an oversubscribed equity placement to new and existing institutional and sophisticated investors...
Race investor briefing & updated presentation
Race investor briefing & updated presentation
Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updatedinvestor presentation and invite investors to join a special online investor briefing. Updated Presentation Investor Briefing Invitation Investors are invited to attend a...
Race Initiates Heart Safety Preclinical Study for Bisantrene
Race Initiates Heart Safety Preclinical Study for Bisantrene
Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle to investigate the heart safety Bisantrene offers over current anthracycline therapeutics....
Race appoints Dr David Fuller Chief Medical Officer
Race appoints Dr David Fuller Chief Medical Officer
20 April 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Dr David Fuller as Chief Medical Officer (CMO). This appointment follows the announcement by Race on 19 February 2021...
City of Hope Professor Jianjun Chen joins Race’s Scientific Advisory Board
City of Hope Professor Jianjun Chen joins Race’s Scientific Advisory Board
16 April 2021 – Race Oncology Limited (“Race”) is pleased to advise that it has appointed Professor Jianjun Chen of the City of Hope Hospital, Los Angeles, to its Scientific Advisory Board (SAB). I...
Second independent study shows Bisantrene inhibits FTO
Second independent study shows Bisantrene inhibits FTO
15 April 2021 – Race Oncology Limited (“Race”) is pleased to share details of a recent scientific publication in the prestigious journal Nature Communication, confirming Bisantrene is a highly effective inhibitor of the Fat...
Race Investor Update March 2021
Race Investor Update March 2021
31 March 2021 – Race Oncology Limited (“Race”) is pleased to update our shareholders on progress of our clinical and preclinical programs under the Three Pillars strategy, originally outlined at the Annual General Meeting...
Race Initiates Extramedullary AML Preclinical Study
Race Initiates Extramedullary AML Preclinical Study
Race Oncology Limited (“Race”) is pleased to announce that it has entered into a new collaborative preclinical research program with The University of Newcastle. This work will be led by the eminent cancer researcher,...
